Pharma News
20 Apr 2025 to 26 Apr 2025
Apr 26, 2025
Affordable pricing and the expiration of patents drive growth in the generic pharmaceuticals sector | London Daily News
The global generic drugs market is led by North America, holding over 39% market share in 2024, with significant contributions from the pure and oral generics segments. Key players like Mylan N.V. (Viatris), Teva Pharmaceutical, and Pfizer are focusing on R&D and biosimilars. Despite challenges like price erosion and consumer skepticism, advancements in technology are driving sustainable growth in the sector.
Apr 25, 2025
Court Decides in Favor of Semaglutide Compounders Following Declaration of End to Shortage - BioSpace
A Texas judge ruled against compounding pharmacies, blocking their attempt to continue producing copycat versions of Novo Nordisk's semaglutide, marketed as Ozempic and Wegovy. The ruling supports the FDA's declaration that the semaglutide shortage is over. The Outsourcing Facilities Association, which filed the lawsuit, argued the FDA's decision was arbitrary, but the judge dismissed these claims.
Apr 25, 2025
Senate Moves Forward with Legislation on Intellectual Property and Drug Pricing Despite Worries About Innovation | JD Supra
A Senate panel has advanced bipartisan bills aimed at reforming intellectual property and reducing prescription drug costs. Key proposals include the Drug Competition Enhancement Act and the Affordable Prescriptions for Patients Act, targeting anticompetitive practices. However, these measures may complicate IP protection for drug manufacturers. The bills also seek to improve efficiency in the pharmaceutical sector through enhanced collaboration and transparency.
Apr 25, 2025
Pharmaceutical companies prepare for tariffs under Trump administration | The Manila Times
Major drugmakers, including Bristol Myers Squibb, Merck & Co, Sanofi, and Roche, exceeded quarterly earnings expectations despite challenges like sector-specific tariffs and drug price reductions. Bristol Myers Squibb even raised its profit forecast, showcasing resilience amid corporate earnings volatility.
Apr 25, 2025
Federal court decision limits cheaper alternatives to Ozempic and Wegovy - USA Today
Novo Nordisk secured a court victory limiting compounding pharmacies from selling cheaper versions of its weight-loss drug Wegovy and diabetes medication Ozempic, both containing semaglutide. A federal judge denied a request for a preliminary injunction from the Outsourcing Facilities Association, affirming the FDA's declaration that the semaglutide shortage is over.
Apr 25, 2025
Dr. Reddy's targets the international GLP-1 market with the launch of a generic drug following patent expiration | Hyderabad News
Dr Reddy's Laboratories plans to enter the GLP-1 drug market by launching generic versions of diabetes and obesity treatments like Semaglutide as patents expire from 2026. Co-chairman GV Prasad emphasized the importance of both innovator and generic companies in ensuring affordability and innovation in pharmaceuticals. The company aims to roll out around 15 GLP-1 drugs globally, targeting early patent expirations.
Apr 25, 2025
Court Decides in Favor of Semaglutide Compounders Following End of Shortage - BioSpace
A Texas judge ruled against compounding pharmacies, blocking their attempt to continue producing copycat versions of Novo Nordisk's semaglutide, marketed as Ozempic and Wegovy. The ruling supports the FDA's declaration that the semaglutide shortage is over. The Outsourcing Facilities Association, which filed the lawsuit, argued the FDA's decision was arbitrary, but the judge dismissed these claims.
Apr 25, 2025
Novo Nordisk's legal victory restricts the production of numerous compounded versions of Wegovy and Ozempic - CNBC
Novo Nordisk achieved a significant legal victory, restricting compounding pharmacies from producing cheaper versions of its diabetes drug Ozempic and weight-loss treatment Wegovy. A Texas federal judge denied a request from the Outsourcing Facilities Association to continue making copies of semaglutide, affirming the FDA's determination that the drug shortage is resolved. Novo Nordisk has initiated over 100 lawsuits to protect patient safety.
Apr 24, 2025
NeuroSense Therapeutics is nearing a significant pharmaceutical agreement with its ALS treatment...
NeuroSense Therapeutics (NASDAQ: NRSN) is in advanced discussions for a transformative partnership with a global pharmaceutical company to commercialize its ALS therapy, PrimeC. The drug, which combines ciprofloxacin and celecoxib, has shown a 58% improvement in survival rates. The partnership could fund a Phase 3 trial set for H2 2025, with potential Canadian sales of $100-150 million annually.
Apr 24, 2025
Sanofi's quarterly earnings rise thanks to Dupixent and other recent medications; outlook remains the same - KFGO
Sanofi reported a first-quarter profit of €2.90 billion, exceeding analyst expectations, driven by strong sales of its anti-inflammatory drug Dupixent, which rose 20.3% to €3.48 billion. Despite this success, the company maintained its full-year forecasts amid concerns over potential U.S. tariffs on pharmaceuticals. Sanofi also noted a 54.9% increase in sales of its new treatment Beyfortus.
Apr 24, 2025
High Potency API Contract Manufacturing Sector Expected to Hit USD 16 Billion by 2032
The global High Potency API (HPAPI) contract manufacturing market, valued at USD 8 billion in 2022, is projected to reach USD 16 billion by 2032, driven by rising cancer rates and demand for precision medicine. Key players include Piramal Pharma Solutions, Lonza, and Pfizer CentreOne. The market is increasingly favoring outsourcing due to cost efficiency and technological advancements.
Apr 23, 2025
Bristol Myers Squibb's schizophrenia medication does not succeed in crucial trial when used alongside antipsychotic treatments.
Bristol Myers Squibb's schizophrenia drug, Cobenfy, has failed a pivotal Phase 3 trial aimed at expanding its use as an adjunct to atypical antipsychotics. While preliminary results showed a numerical change in symptoms, it lacked statistical significance. Analysts have reduced revenue projections for Cobenfy, though some remain optimistic about its potential in treating Alzheimer’s-associated psychosis.
Apr 23, 2025
Reasons Behind Summit Therapeutics' Significant Surge Today - The Globe and Mail
Summit Therapeutics (NASDAQ: SMMT) shares surged 14.7% following positive preliminary results from its phase III HARMONi-6 trial for the lung cancer drug ivonescimab, which showed significant improvement in progression-free survival compared to BeiGene's tislelizumab. The trial, conducted with Akeso (OTC: AKES.F), positions ivonescimab as a potential blockbuster in lung cancer treatment.
Apr 23, 2025
Analysis of the Generic Pharmaceuticals Market: Projected Growth Rate of 5.0% CAGR
The global generic drugs market is projected to grow from USD 424.2 billion in 2023 to USD 691 billion by 2033, driven by rising healthcare costs and patent expirations. However, proposed U.S. tariffs could increase consumer costs and disrupt supply chains, potentially leading to drug shortages. North America leads the market, while Asia Pacific is expected to grow rapidly.
Apr 23, 2025
Eli Lilly takes legal action against firms marketing competing versions of its weight loss medication - NPR
Eli Lilly is suing four telehealth companies—Mochi Health, Willow Health, Fella Health, and Henry Meds—for allegedly selling illegal compounded versions of its weight loss drug Zepbound, which contains the active ingredient tirzepatide. The lawsuits follow the end of a two-year shortage of tirzepatide, with Lilly asserting that these companies are deceiving patients and violating FDA regulations.
Apr 23, 2025
Eli Lilly takes legal action against telehealth platforms offering imitation Zepbound - Sherwood News
Eli Lilly has filed lawsuits against four telehealth platforms—Mochi Health, Fella Health, Willow Health, and Henry Meds—for selling compounded versions of its weight-loss drug Zepbound, despite the FDA declaring an end to its shortage. The lawsuits highlight concerns over the misuse of compounding regulations, potentially impacting other companies like Hims & Hers that offer personalized versions of semaglutide.
Apr 22, 2025
Pfizer Defends Its Leading Heart Drug as Alnylam and BridgeBio Join the Competition
Alnylam and BridgeBio Pharma have entered the ATTR amyloidosis market, challenging Pfizer's tafamidis (Vyndaqel, Vyndamax, Vynmac). BridgeBio's Attruby received FDA approval in November 2024, while Alnylam's Amvuttra was approved in March. Pfizer reported $5.4 billion in tafamidis sales for 2024, but competition is expected to intensify as both companies aim for market share in this growing sector.
Apr 22, 2025
Ongoing Discussion Surrounding Patents for Second Medical Uses - Mondaq
Second medical use patents are crucial for repurposing existing drugs, offering new treatment options. Notable examples include aspirin for heart attack prevention, thalidomide for leprosy, minoxidil for hair growth, and sildenafil for erectile dysfunction. The European Patent Office emphasizes stringent criteria for these patents, ensuring they demonstrate inventive steps and sufficient evidence to support therapeutic claims.
Apr 22, 2025
FDA grants approval for Dupixent to treat Chronic Spontaneous Urticaria in individuals aged 12 and older.
The FDA has approved Dupixent (dupilumab) for treating chronic spontaneous urticaria (CSU) in patients aged 12 and older, a significant advancement for Sanofi and Regeneron. This approval follows successful Phase 3 trials demonstrating Dupixent's efficacy alongside antihistamines. With over 300,000 eligible patients in the US, Dupixent now addresses CSU, asthma, eczema, and chronic lung disease, reinforcing its market dominance.
Apr 22, 2025
Reasons Bristol Myers Squibb (BMY) is Considered a Strong Long-Term Value Investment - Yahoo Finance
Bristol Myers Squibb (BMY) is highlighted as a strong value stock, boasting a Value Style Score of B and a Zacks Rank #3 (Hold). The company, known for its immuno-oncology drug Opdivo and other treatments, shows impressive earnings potential with a forward earnings multiple of 7.2X and a PEG Ratio of 1.8. Analysts have recently increased earnings estimates for BMY.
Apr 22, 2025
Regeneron and Biocon Reach Agreement in Patent Dispute Over Eylea Biosimilar - Bloomberg Law News
A federal judge has lifted an order blocking a biosimilar of Regeneron Pharmaceuticals Inc.’s Eylea, approving a deal that resolves patent litigation with Mylan Pharmaceuticals Inc. and Biocon Ltd. The ruling dismisses all claims, allowing the rivals to market their own macular degeneration drug in the US.
Apr 20, 2025
Sanofi and Regeneron's blockbuster medication Dupixent receives FDA approval for a skin inflammatory condition.
Sanofi and Regeneron Pharmaceuticals' Dupixent has received FDA approval for chronic spontaneous urticaria (CSU), marking its seventh indication. This approval offers a new treatment option for patients aged 12 and older whose symptoms persist despite antihistamine use. Dupixent, a monoclonal antibody targeting IL-13 and IL-4, aims to improve outcomes for the estimated 1.7 million affected individuals in the U.S.
Apr 20, 2025
Should You Consider Investing in AbbVie Stock? - Yahoo
AbbVie (NYSE: ABBV) faces challenges after a $9 billion drug acquisition failed clinical trials, causing stock volatility. Despite concerns over the Trump administration's impact, AbbVie has successfully transitioned from Humira, with new drugs Skyrizi and Rinvoq driving revenue growth. The company remains a strong dividend stock, boasting over 50 consecutive annual increases. Analysts predict 12% earnings growth in the coming years.
